Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer clinical trial (NCT05861271). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer clinical trial (NCT05861271). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from pyrotinib and capecitabine?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer clinical trial (NCT05861271). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer clinical trial (NCT05861271). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects or my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer clinical trial (NCT05861271). Contact the study team or your healthcare provider for specific answers.

Question 6

Will my participation in this trial affect my ability to receive other treatments in the future?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer clinical trial (NCT05861271). Contact the study team or your healthcare provider for specific answers.

What this study is about